PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Barbiturates”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 379 records · Page 21Linked to original sources

Effect of barbituric acid on the high pressure nervous syndrome in the rat.

Male Sprague-Dawley rats were compressed in helium-oxygen mixture at a rate of 3 bar/min. Compression ended once the first convulsion was seen. Saline or barbituric acid at 1 or 2% were infused continuously during compression at a rate of 9.49 ml/h (tail vein). With barbituric acid at 1%, coarse tremor and convulsions appeared at higher pressures than in saline controls. No significant change was observed with 2% barbituric acid compared to saline controls. Barbituric acid which is nonanesthetic had some anti-high pressure nervous syndrome (HPNS) activity which is dose dependent. These results suggest that anti-HPNS activity of these different compounds involves at least one site which is different from that responsible for anesthetic activity.

Animals↗

Changes in serotonin turnover and the brain sensitivity to barbiturates by disulfiram treatment in rats.

The influence of intraperitoneal administration of disulfiram on the serotonin (5HT) turnover and the brain sensitivity to barbiturates were investigated in rats. Treatment of the animals with 200 mg/kg disulfiram resulted in the prolongation of duration of barbiturate-induced hypnosis. This indication and increment of the brain sensitivity to barbiturates after disulfiram treatment. Under the identical condition, disulfiram caused both the reduction of turnover of 5HT and the elevation of 5HT levels, although this effect was less potent than that of phenobarbital. Furthermore, simultaneous administration of disulfiram and phenobarbital resulted in the severe retardation of 5HT metabolism. These results strongly suggest that disulfiram potentiates the hypnotic action of barbiturates by altering 5HT metabolism in rat brain.

Animals↗

Loss of inhibition in the spinal cord during barbiturate withdrawal.

Three types of inhibition in the spinal cord were studied during barbiturate withdrawal. Cats were made physically dependent on pentobarbital using a standard technique for chronic treatment developed in this laboratory. All animals treated this way developed severe withdrawal signs including spontaneous grand mal type convulsions, upon abrupt drug withdrawal. Animals were prepared for electrophysiological studies 48 hours after the last dose of chronic pentobarbital treatment, near peak intensity of the withdrawal syndrome. Under halothane anesthesia, the neuraxis was sectioned at C1 and both common carotid arteries were ligated. The animal was then respired on room air. The lumbar spinal cord was exposed by laminectomy, a hindleg was dissected to allow stimulation of peripheral nerves and action potentials were recorded from ventral roots L7 and S1 that had been cut near their exits through the dura mater. Recurrent (Renshaw cell-mediated) inhibition was almost totally absent during barbiturate withdrawal. Presynaptic inhibition was also decreased. Postsynaptic inhibition was little affected by barbiturate dependence. These findings indicate that loss of function in inhibitory pathways plays a role in barbiturate dependence and withdrawal.

Action Potentials↗

Enhancement by anesthetic and convulsant barbiturates of GABA binding to rat brain synaptosomal membranes.

All of the anesthetic (amylobarbitone, butobarbitone, pentobarbitone, phenobarbitone, and secobarbitone) and convulsant (5-ethyl-5(3'-methylbut-2-enyl) barbituric acid (3M2B) and 5-ethyl-5-(2'-cyclohexylidene-ethyl) barbituric acid (CHEB) barbiturates tested enhanced the binding of GABA to a carefully prepared P2 membrane fraction from rat brain in a dose-dependent manner. These findings are in agreement with the potentiation of the inhibitory effects of GABA in many neuronal systems by both classes of barbiturates.

Anesthetics↗

Reducing the risk: barbiturate substitution with a benzodiazepine.

A study was carried out in general practice in 85 habitual barbiturate takers, many of whom had been using this hypnotic for over 30 years, to assess the clinical practicability and acceptance of barbiturate substitution with flurazepam. Each barbiturate capsule or tablet being taken by patients was replaced by 15 mg flurazepam, either immediately or by gradual substitution. Patients were followed-up over a period of 6 months. The results showed that 5% of the patients were able to stop hypnotic therapy after initial substitution with flurazepam, a further 7% were maintained on occasional flurazepam and 65% on repeated doses, while 18% continued to take barbiturates.

Adult↗

Potencies of barbiturates in mice selectively bred for resistance or susceptibility to nitrous oxide anesthesia.

To test the possibility that mice selectively bred for resistance (HI mice) and susceptibility (LO mice) to nitrous oxide anesthesia have general differences in central nervous system sensitivity to other depressants, we examined the effects of four barbiturates in these two lines of mice. LO mice given intraperitoneal injections of barbital (275 mg/kg), hexobarbital (120 mg/kg), pentobarbital (65 mg/kg), or secobarbital (50 mg/kg) had significantly (16-46%) longer sleep times than HI mice. Concentrations of barbiturates were significantly (12-73%) greater in the serum and 3-55% greater in the brain on awakening in HI mice than in LO mice. The largest separations in potency between the HI and LO lines occurred with pentobarbital and hexobarbital and the smallest separations with barbital and secobarbital. We concluded that HI and LO mice do have a general resistance and susceptibility to barbiturates, but that the magnitude of the difference in central nervous system sensitivity between the two lines varies among barbiturates.

Anesthesia↗

[Effect of barbiturates on myocardial metabolism and hemodynamics].

In 31 patients with congenital heart disease effects of 5 mg/kg thiopental or 1 mg/kg methohexital on hemodynamics, inotropic state, myocardial metabolism and myocardial oxygen consumption were investigated after cardiac surgery (basic neuroleptanalgesia). In comparison to a control group both barbiturates caused a decrease in stroke volume and arterial pressure. This, however, was mainly attributable to venous pooling and not to a negative inotropic effect. In accordance with the changes in hemodynamics there was a remarkable decrease in myocardial oxygen consumption (5 mg/kg thiopental: Eg--17,7%; 1 mg/kg methohexital: Eg--11,7%). It could be demonstrated that arterial and coronarvenous lactate correlated directly with plasma concentrations of barbiturates. Furthermore it may be possible that the slight increase in free fatty can have deleterious effects on myocardial glucose metabolism. No significant alterations in serum electrolytes concentrations were observed. Plasma concentrations of thiopental and methohexital were determined by specific gaschromatography. In spite of the great interindividual variation of plasma barbiturate concentration there was an equilibrium between arterial and coronarvenous barbiturate levels within two minutes.

Adult↗

Search for CNS active agents: synthesis of N,N'-bis-[potassium-alkyl/aryl carboxylate]-5-arylidene barbituric acids.

5-Arylidene barbituric acids (1--5, Fig. 1) were obtained by the Perkin's condensation between the corresponding aryl aldehyde and active methylene group of barbituric acid. By the condensation of these 5-arylidene barbituric acids with different alkyl/aryl-chloroacids, fifteen new N,N'bis[potassium-alkyl/aryl carboxylate]-5-arylidene barbituric acids (6--8 Fig. 1) were prepared. Eight of the fifteen final compounds were screened for their pharmacological actions on CNS. They have shown irregular behavioral changes on the CNS; some of them were the CNS stimulants, whereas others were CNS depressants at 1/5 of ALD50 dose level (316--1000 g/kg).

Animals↗

[Effects of in vivo pretreatment with various barbiturates on lidocaine metabolism in rat liver microsomes].

In male Wistar rats, we studied the effects of in vivo pretreatment with phenobarbital (PB), amobarbital (AB), hexobarbital (HB), pentobarbital (PT) or thiamylal (TI) on hepatic microsomal enzymes, and on deethylation of lidocaine in the microsomes. The rats of pretreatment groups received 0.1 ml of the above barbiturates (320 mumol.kg-1) and the control group received intramuscular injection of 0.9 % NaCl solution for 4 days. NADPH-cytochrome C reductase of the PB and AB groups increased significantly in activity and cytochrome b5 of only PB group increased in content. After the pretreatment with PB, TI produced higher microsomal cytochrome P-450 contents than in the control group. The potency of P-450 induction was in descending order of PB, TI, AB, HB and PT. Also we found the positive linear relationship between the potency of P-450 induction and the elimination half time (t1/2 beta) of the barbiturates. The activities of lidocaine deethylase with microsomes per P-450 of the pretreated rats with these five barbiturates (PB, AB, HB, PT and TI) were 2.4, 1.9, 2.2, 1.5 and 2.2 times of control values, respectively. Based on these results, we conclude that lidocaine deethylase activity of P-450 is increased by these five barbiturates whether levels of P-450 are increased quantitatively, or not.

Animals↗

Common pathways of cytochrome P450 gene regulation by peroxisome proliferators and barbiturates in Bacillus megaterium ATCC14581.

Bacillus megaterium contains a barbiturate-inducible cytochrome P450BM-3, which catalyzes the hydroxylation of fatty acids. We report the intriguing finding that peroxisome proliferators, a major class of epigenetic carcinogen, are also extremely potent inducers of this enzyme being up to 50-fold more potent than one of the most effective barbiturates, secobarbital. Similar to barbiturates, the mechanism of induction appears to involve the direct binding of the peroxisome proliferator to the transcriptional repressor (Bm3R1), resulting in its dissociation from its DNA operator. These observations provide evidence that peroxisome proliferators can interact with a transcription factor to modulate gene expression. The data also demonstrate that the effects of these compounds are highly conserved through evolution and that there are important common denominators in the regulation of gene expression by peroxisome proliferators and the barbiturates. Evidence is presented to indicate that this may involve effects on unsaturated fatty acid homeostasis.

Bacillus megaterium↗

Barbiturate-reinforced responding in rhesus monkeys: comparisons of drugs with different durations of action.

The rate and pattern of pressing a lever was studied in rhesus monkeys under conditions where each press led to the intravenous injection of a barbiturate or of saline. The reinforcing effect of the barbiturate was indicated by higher rates of responding on the lever that delivered drug than on the lever that did not and by lower rates of responding when saline was delivered instead of the barbiturate. Responding increased and was maintained by the following ranges of dose/injection: barbital (2.5-10.0 mg/kg), pentobarbital (0.25-4.0 mg/kg), amobarbital (0.25-4.0 mg/kg), thiopental (0.50-4.0 mg/kg) and methohexital (0.125-2.0 mg/kg). Response rates were inversely related to the dose delivered with each injection for each of the barbiturates over these ranges. Within 3-hour access periods, injections tended to occur in bursts followed by pauses.

Animals↗

Production of hydrogen peroxide by alveolar macrophages. Effect of barbiturates.

Production of hydrogen peroxide by rat lung alveolar macrophages represents one of the key events in the inflammatory process. For the interpretation of the in vitro measurements it is important to control all possible interfering influences. The present work documents that the type of anaesthesia might critically influence the observed results. H2O2 production was measured in isolated rat alveolar macrophages by luminol chemiluminescence catalyzed by horseradish peroxidase. Three different mechanisms of H2O2 production were observed after stimulation of cells with a chemotactic peptide (FMLP), phorbol ester (PMA), and during cell adherence. All these activities were influenced independently by the treatment with barbiturates, which both stimulated or inhibited the H2O2 production, depending on the barbiturate concentration. As the effective barbiturate concentrations were found to be within the range used for the anaesthesia of experimental animals, the presented results imply that barbiturates are not suitable for experiments in which the production of reactive oxygen species by phagocytes is measured, and that other anaesthetics should be tested.

Animals↗

Pharmacokinetics of some homologous series of barbiturates in the intact rat and in the isolated perfused rat liver.

The pharmacokinetics of a number of 5,5-dialkyl-substituted barbiturates was studied both in the intact rat and in the isolated perfused rat liver. The half-life or the clearance of a reference compound was used as parameter for the drug metabolic activity of the animal and perfused liver. The rate of elimination of the barbiturates was structure-dependent and seemed to be correlated with the lipophilicity of the compounds which was expressed as the octanol-water and hepatocytes-water partition coefficient. Three features could be distinguished. Firstly, there was a decrease in half-life with the introduction of a larger alkyl side chain. Secondly, substitution of a bromoallyl instead of an allyl group had the same effect and thirdly, a more rapidly eliminated barbiturate could be obtained by the introduction of a methyl group onto the nitrogen of the barbiturate nucleus. The elimination clearance constants relative to the heptabarbital clearance were in the same order of magnitude as those found in man. This result suggests that it is possible to predict the clearance values in man by studying relative values in rats.

Animals↗

GC/MS confirmation of barbiturates in blood and urine.

A gas chromatography-mass spectrometric method is described for the quantitative measurement of 6 commonly used barbiturates in blood and urine specimens. The targeted barbiturates are butalbital, amobarbital, pentobarbital, secobarbital, mephobarbital and phenobarbital. They are recovered along with the internal standard, tolybarb, from blood and urine using liquid extraction then alkalated to form the N-ethyl derivatives. The ethylated barbiturates have symmetrical peaks which are well separated from each other on a non-polar methylsilicone capillary column. The derivatives on a non-polar methylsilicone capillary column. The derivatives facilitate quantitations between 50 and 10,000 ng/mL. The day-to-day CVs for all 6 barbiturates were between 4 and 9% at 200 and 5000 ng/mL. The method has been extended for identifying other acidic drugs and drug metabolites. They are mainly non-steroidal anti-inflammatory drugs, diuretics, and anticonvulsants. An additional 83 compounds can be qualitatively identified.

Analgesics↗

Barbiturate abuse.

The barbiturates are the drugs most commonly abused, and in his paper Dr d'Orban gives the general reader a clear, sober account of the drugs so abused, the pattern of abuse and the prevalence of the abuse of barbiturates. Sadly, some addicts add barbiturates to their abuse of other drugs upon which they depend. Dr d'Orban concludes his survey by telling how those addicted to barbiturates obtain the drugs and the hazards to which they expose themselves.

Adolescent↗

A novel GABAA antagonist [3H]SR 95531: microscopic analysis of binding in the rat brain and allosteric modulation by several benzodiazepine and barbiturate receptor ligands.

Recent reports have demonstrated that the synthetic gamma-aminobutyric acid (GABA)-derivative, SR 95531 [2-(3'-carbethoxy-2'-propyl)-3-amino-6-paramethoxy-phenyl-pyrid azinium bromide], possesses selective GABAA antagonistic properties. Because of its potency for recognition of GABAA sites, this agent has been used to identify GABAA receptors. In the present investigation, we studied the binding of [3H]SR 95531 to tissue sections of rat brain using microscopic analysis of receptor localization. The appropriate binding conditions for defining GABAA receptors with this radioligand were obtained by determining the dissociation and association kinetics, and performing saturation and displacement studies. Using membrane preparations from whole rat brain (or brain regions representing cortex, striatum, hippocampus, midbrain-thalamus, medulla-pons and cerebellum), saturation and displacement studies were analyzed, and allosteric modulation of [3H]SR 95531 binding was examined by including several benzodiazepine and barbiturate receptor ligands in the incubation media. To assess the stereoselective properties of [3H]SR 95531 binding in rat membranes, numerous barbiturates were added during the incubation. The binding of [3H]SR 95531 was demonstrated to be saturable, specific and to bind with relatively high affinity to low-affinity GABAA sites. Scatchard analysis performed on saturation data of binding to tissue sections showed a dissociation constant (KD) of 42.4 nM and a maximum number of binding sites (Bmax) of 105.8 fmol/mg tissue. Microscopic analysis showed that intermediate to high densities of [3H]SR 95531 binding occurred in brain regions containing intermediate to high densities of low-affinity GABAA receptor sites. The binding of [3H]SR 95531 to membranes also appeared to occur at low-affinity GABAA sites. Results from competition studies demonstrated that [3H]SR 95531 is displaceable by GABAA agents and displaced preferentially by GABAA antagonists. Scatchard analysis of saturation experiments from membrane preparations indicated that the KD and Bmax from the centrifugation assay was 53.0 nM and 4.26 pmol/mg protein, respectively. Using the filtration assay, binding to membranes yielded a KD value of 45.6 nM and a Bmax of 0.77 pmol/mg protein. The allosteric modulation data demonstrated that numerous benzodiazepine and barbiturate agents inhibited [3H]SR 95531 binding and this varied according to brain region. Several barbiturates included in the incubation media exhibited a stereoselective inhibition of [3H]SR 95531 binding to whole rat brain membranes.(ABSTRACT TRUNCATED AT 400 WORDS)

Allosteric Regulation↗

Barbiturate coma for severe, refractory vasospasm following subarachnoid haemorrhage.

OBJECTIVE: To document the outcome of patients treated with barbiturate coma for severe symptomatic angioplasty-resistant vasospasm. To compare mortality with that predicted by admission APACHE II score, and neurological outcome with that of historical controls treated with barbiturate coma for vasospasm, and with historical controls with delayed ischaemic deficits from vasospasm treated with nimodipine. DESIGN: Cohort study. SETTING: Neurosurgical Intensive Care Unit of tertiary referral university teaching hospital. PATIENTS: Eleven (6.7%) of 164 consecutive patients with aneurysmal SAH managed according to our protocol who were treated with thiopentone-induced burst suppression coma for severe symptomatic, angioplasty-resistant vasospasm. INTERVENTIONS: Chart, database and literature review. MEASUREMENTS AND RESULTS: All 11 patients survived to hospital discharge (mortality 0%) compared with first-day APACHE II predicted mortality of 30.6% (p=0.15). Outcome at 6 months was: good recovery 8/11 (72.7%), moderate disability 2/11 (18.2%), vegetative survival 1/11 (9.1%). Ten of 11 (90.9%) had a good neurological outcome compared with 50.6% of historical controls with delayed ischaemic deficit from vasospasm (odds ratio 9.78, 95% confidence interval 1.24-77.0, p=0.02), and 0% of previously reported patients treated with barbiturate coma for vasospasm (p < 0.01). CONCLUSION: Our results are better than previously published outcomes and suggest formal evaluation of barbiturate coma in the treatment of severe resistant symptomatic vasospasm following SAH is warranted.

APACHE↗

Recombinant human 5-HT3A receptors in outside-out patches of HEK 293 cells: basic properties and barbiturate effects.

The patch-clamp technique was used on excised (outside-out) patches to characterize h5-HT3A receptors stably transfected in HEK 293 cells and to compare the effects of the barbiturate anaesthetics methohexital and pentobarbital on this ligand-gated cation channel. At negative membrane potentials 5-HT induced inward currents in a concentration-dependent manner (EC50=8.6 microM, Hill coefficient =1.5). The mean peak current induced by 30 microM 5-HT was -110 pA at -100 mV. The 5-HT3A receptor antagonist ondansetron (0.3 nM) reversibly inhibited the 5-HT (30 microM) signal by 70% and at 3 nM it abolished the response. Methohexital and pentobarbital inhibited 5-HT-induced (30 microM) currents in a concentration-dependent manner. The maximal inhibition with a given methohexital or pentobarbital concentration was reached when the respective drug was applied 45 s prior to and during the 2-s 5-HT pulse (IC50 values=95 microM and 127 microM, Hill coefficient = -1.0 and -1.6, respectively). Although the barbiturates were, thus, equipotent, their effects differed substantially with respect to the dependence on the time schedule of application to the patches: the potency of methohexital was virtually maximal when the drug was applied exclusively 45 s before the agonist pulse, but its inhibitory potency decreased considerably when it was exclusively applied during the 2-s 5-HT pulse (IC50=380 microM). Conversely, pentobarbital was almost maximally potent in inhibiting the 5-HT signal when it was exclusively coapplied with this agonist, but its inhibitory potency was considerably lower (IC50 approximately 500 microM) when applied exclusively 45 s before 5-HT. Another difference between both barbiturates involves the rate of inactivation of 5-HT3 receptor-mediated currents: whereas high concentrations of methohexital (> or = 300 microM) were necessary to induce moderate (< or = twofold) acceleration of this parameter, pentobarbital produced such an effect at all concentrations and the extent of acceleration increased with increasing concentration (1.5- to fivefold). In conclusion, two barbiturates, chemically closely related but of different lipophilicity, clearly differ with respect to the kinetics of their effect on 5-HT3 receptor channels; one possible explanation involves drug access to an amphipathic site of action via both an aqueous and a hydrophobic pathway. Pentobarbital, in contrast to methohexital, inhibits hS-HT3A receptor-mediated currents at anaesthetic concentrations (approximately 90 microM).

Anesthetics, Intravenous↗